NO852427L - PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS - Google Patents

PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS

Info

Publication number
NO852427L
NO852427L NO852427A NO852427A NO852427L NO 852427 L NO852427 L NO 852427L NO 852427 A NO852427 A NO 852427A NO 852427 A NO852427 A NO 852427A NO 852427 L NO852427 L NO 852427L
Authority
NO
Norway
Prior art keywords
procedure
substances
reacted
protein
blood
Prior art date
Application number
NO852427A
Other languages
Norwegian (no)
Inventor
Laszlo Dede
Laszlone Dede
Original Assignee
Caola Kozmetikai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caola Kozmetikai filed Critical Caola Kozmetikai
Publication of NO852427L publication Critical patent/NO852427L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983Blood, e.g. plasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Description

Foreliggende oppfinnelse angår fremstilling av helse-konserverende og regenererende preparater, til hvilke humane blodkarakteristika for artene, typen av den givende levende organisme, f.eks. tilhørende blodtype A, B, AB, 0, Rh-positiv, Rh-negativ eller elementer derav og/eller proteiner erholdt derfra og/eller vev avledet fra animalske organismer av gitte arter eller typer og/eller elementene derav og/eller proteiner erholdt derfra påføres per se, og/eller omsettes med uorganiske substanser, f.eks. med elementer som har sporelement-funksjon i organismen, eventuelt sammen med kjente additiver, hjelpemidler, fyllstoffer, som kan anvendes ved fremstilling av helse-, kropps- og hud-konserverende preparater, og/eller i form av innvortes administrerte preparater. The present invention relates to the production of health-preserving and regenerating preparations, to which human blood characteristics for the species, the type of the donor living organism, e.g. associated blood type A, B, AB, 0, Rh-positive, Rh-negative or elements thereof and/or proteins obtained therefrom and/or tissues derived from animal organisms of given species or types and/or the elements thereof and/or proteins obtained therefrom applied per se, and/or reacted with inorganic substances, e.g. with elements that have a trace element function in the organism, possibly together with known additives, auxiliaries, fillers, which can be used in the production of health, body and skin preserving preparations, and/or in the form of internally administered preparations.

Det største særtrekk ved foreliggende oppfinnelseThe greatest distinctive feature of the present invention

ligger i anvendelse av elementene og plasmaproteiner av humant blod, ved omsetning av disse med uorganiske ioner og ved anvendelse av det erholdte produkt for kroppskonserverende bruk utvortes og/eller innvortes, f.eks. peroralt. lies in the use of the elements and plasma proteins of human blood, by reacting these with inorganic ions and by using the obtained product for body preservative use externally and/or internally, e.g. orally.

Det er kjent at mineralske substanser, sporelementene, spiller en signifikant rolle ved funksjoneringen av levende organismer også i meget små konsentrasjoner, i første rekke fordi de er komponenter av flere enzymer, enzymaktivatorer eller inhibitorer som deler av større molekyler eller ved interaksjon med disse molekyler slik at de således spiller en regulerende rolle ved organismens funksjonering. Som kjent har sporelementene en spesifikk aktivitet i den levende organisme til tross for det faktum at de er inaktive in vitro. Sporelementene utviser deres spesifikke og nødvendige effekt ved binding til de såkalte bærermolekyler og kommer derved i biologisk aktiv transport. Slike store molekyler er plasmaproteiner. Koblingen mellom sporelementene og proteinene vil etableres i organismen når betingelsene for dette sikres. It is known that mineral substances, the trace elements, play a significant role in the functioning of living organisms even in very small concentrations, primarily because they are components of several enzymes, enzyme activators or inhibitors as parts of larger molecules or by interaction with these molecules such that they thus play a regulatory role in the organism's functioning. As is known, the trace elements have a specific activity in the living organism despite the fact that they are inactive in vitro. The trace elements exhibit their specific and necessary effect by binding to the so-called carrier molecules and thereby enter into biologically active transport. Such large molecules are plasma proteins. The connection between the trace elements and the proteins will be established in the organism when the conditions for this are ensured.

Denne kobling er imidlertid ikke alltid egnet og svarer ikke til den nødvendige grad slik at effekten av sporelementene ikke fremkommer, enzymene med egnet aktivitet dannes ikke slik at hudsykdommer og mangelsykdommer vil utvikles. Ifølge litteraturdata kan mangel på sporelementer fremkalle cancerøs omdannelse i organismen, i hvilke tilfeller innføring av egnede protein/sporelementaddukter i organismen kan være for- delaktig- Således kan sporelementene ikke komme til de nød-vendige steder i organismen og vil ikke komme i en biologisk aktiv tilstand uten en transmitter og vil således ikke delta i de vitale prosesser slik at helsetilstanden vil bli ned-satt. Dette fremkommer eksempelvis når det gjelder mangel på sink, også når det gjelder den ytre forandring av huden. Sink er en komponent i minst 30 enzymer og spiller en avgjørende rolle i hudens proteinsyntese. Mangel på kobber bevirker eksempelvis at kvaliteten på ull fra sauer forringes da den fører til utilstrekkelig proteinsyntese. Sinkmetalloenzymene deltar i syntesen av DNS og RNS og mangel på disse inhiberer overføringen av genetisk informasjon som er nødvendig for dannelse av proteiner, fremkaller dvergtilbøyelighet og inhiberer regenerering av huden. Når det gjelder kobber-mangel vil hudens kollagenstruktur skades. However, this connection is not always suitable and does not respond to the necessary degree so that the effect of the trace elements does not appear, the enzymes with suitable activity are not formed so that skin diseases and deficiency diseases will develop. According to literature data, a lack of trace elements can induce cancerous transformation in the organism, in which cases the introduction of suitable protein/trace element adducts into the organism can be beneficial - Thus, the trace elements cannot get to the necessary places in the organism and will not get into a biologically active condition without a transmitter and will thus not participate in the vital processes so that the state of health will be reduced. This appears, for example, when it comes to a lack of zinc, also when it comes to the external change of the skin. Zinc is a component of at least 30 enzymes and plays a crucial role in the skin's protein synthesis. Lack of copper, for example, causes the quality of wool from sheep to deteriorate as it leads to insufficient protein synthesis. The zinc metalloenzymes participate in the synthesis of DNS and RNS and a lack of these inhibits the transfer of genetic information necessary for the formation of proteins, induces dwarfism and inhibits skin regeneration. When it comes to copper deficiency, the skin's collagen structure will be damaged.

Ifølge forsøk kan de ovenfor angitte ulemper ikke elimineres under anvendelse av mineralsubstanser per se, hvilket kan bevises ved at enkel tilsetning av jernsalter ikke vil føre til legning av sykdommer oppstått på grunn av jernmangel. Detaljene ved aktiveringsprosessene for sporelementene er ikke kjent men det er allerede bevist at de trenger et bærermolekyl slik at de kan spille deres viktige biologiske rolle. According to experiments, the above-mentioned disadvantages cannot be eliminated using mineral substances per se, which can be proven by the simple addition of iron salts will not lead to the healing of diseases caused by iron deficiency. The details of the activation processes for the trace elements are not known, but it has already been proven that they need a carrier molecule so that they can play their important biological role.

Målet ved foreliggende oppfinnelse er å eliminere de ovenfor angitte ulemper. Hovedtrekket ved foreliggende oppfinnelse består i at ved anvendelse av proteiner og sporelementer som er arts- eller type-spesifikke erholdes et addukt fra hvilket den aktive absorpsjon av sporelementer sikres, hvorved helse-konserverende og hud-regenererende preparater kan fremstilles. Anvendelse av de ovenfor angitte komponenter eliminerer den uønskede antigeneffekt, fremkaller ikke aller-giske reaksjoner og sikrer en hurtig regenerering av de skadede celler i huden og den tilstrekkelige funksjon av metallo-enzymene. Det er funnet at den hud-regenererende krem fremstilt ifølge oppfinnelsen har leget eksempelvis et sår på nesen av plommestenstørrelse som hadde væsket i 15 år og som ble betraktet som uhelbredelig, ved påføring av denne to ganger pr. dag i 8 dager slik at huden på nesen var blitt fullstendig regenerert og såret ikke etterlot noe spor. I andre tilfeller har kremen fremstilt ifølge oppfinnelsen regenerert avskallet hud på en rotte i løpet av 6 dager i en slik grad at selv hår er vokst ut på den avskallede hudoverflate mens huden på kontrolldyret var fullstendig skadet. Kremen ifølge oppfinnelsen kan påføres med fordel eksempelvis på hud med psoriasis. The aim of the present invention is to eliminate the above-mentioned disadvantages. The main feature of the present invention is that by using proteins and trace elements that are species- or type-specific, an adduct is obtained from which the active absorption of trace elements is ensured, whereby health-preserving and skin-regenerating preparations can be prepared. Use of the above-mentioned components eliminates the unwanted antigenic effect, does not cause allergic reactions and ensures a rapid regeneration of the damaged cells in the skin and the adequate functioning of the metallo-enzymes. It has been found that the skin-regenerating cream produced according to the invention has healed, for example, a pumice-sized wound on the nose which had been oozing for 15 years and which was considered incurable, by applying it twice a week. day for 8 days so that the skin on the nose was completely regenerated and the wound left no trace. In other cases, the cream produced according to the invention has regenerated peeled skin on a rat within 6 days to such an extent that even hair has grown on the peeled skin surface, while the skin of the control animal was completely damaged. The cream according to the invention can be applied with advantage, for example, to skin with psoriasis.

Det helse-konserverende og regenererende preparatThe health-preserving and regenerating preparation

ifølge oppfinnelsen kan også påføres innvortes. Adduktet av sporelementene og de arts, typespesifikke proteiner sikrer de absorberbare sporelementer også for enzymsystemet som er nød-vendig for funksjonering av hele organismen. Dette muliggjør en optimal funksjonering av organismen idet man tar i betraktning en spesfikk status av organismen. according to the invention can also be applied internally. The adduct of the trace elements and the species-specific proteins ensures the absorbable trace elements also for the enzyme system which is necessary for the functioning of the entire organism. This enables optimal functioning of the organism, taking into account a specific status of the organism.

Følgelig angår oppfinnelsen et artsspesifikt, type-spesifikt helse-konserverende preparat som kan påføres både innvortes og utvortes, og som erkarakterisert vedat det fremstilles fra sporelementer og proteiner, proteinholdige substanser som er karakteristiske for de gitte arter og typer hvorpå det erholdte preparat anvendes for helse-konservering av en levende organisme av samme art og type. Accordingly, the invention relates to a species-specific, type-specific health-preserving preparation which can be applied both internally and externally, and which is characterized by the fact that it is produced from trace elements and proteins, proteinaceous substances which are characteristic of the given species and types on which the obtained preparation is used for health - conservation of a living organism of the same species and type.

Fremstilling av de helse-konserverende og regenererende preparater ifølge oppfinnelsen illustreres i de etterfølgende Production of the health-preserving and regenerating preparations according to the invention is illustrated in the following

- ikke eksempler.- not examples.

Eksempel 1Example 1

100 ml humant blod tilhørende gruppe A ble separert100 ml of human blood belonging to group A was separated

for plasma og blodelementer. Til den erholdte plasmavæske ble tilsatt 1 g natriumbicarbonat og reaksjonsblandingen ble oppvarmet til 80°C. Proteinpresipitatet ble fraskilt, og etter tørking eller til det fremdeles våte plasmaprotein med et tørrstoffinnhold på 3,5 g ble 70 ml av en vandig løsning inneholdende 35 ug jern(II), 35 ug sink(II), 10 ug kobber(II), for plasma and blood elements. 1 g of sodium bicarbonate was added to the plasma fluid obtained and the reaction mixture was heated to 80°C. The protein precipitate was separated, and after drying or to the still wet plasma protein with a dry matter content of 3.5 g, 70 ml of an aqueous solution containing 35 µg iron(II), 35 µg zinc(II), 10 µg copper(II),

10 ug sølv(I), 1 ug krom(III), 2 ug mangan(XI), 1 ug gull(III) ioner såvel som 1 ug bor og 1 ug molybdenioner tilsatt. Reaksjonsblandingen ble behandlet i et bad på 100°C i 60 minutter, og etter avkjøling ble 100 g krem fremstilt fra den er- 10 ug silver(I), 1 ug chromium(III), 2 ug manganese(XI), 1 ug gold(III) ions as well as 1 ug boron and 1 ug molybdenum ions added. The reaction mixture was treated in a bath at 100°C for 60 minutes, and after cooling, 100 g of cream was prepared from the

holdte substans på kjent måte innen kosmetikkfaget. Det således erholdte produkt er et glimrende hudmiddel som er egnet for behandling av skadede hudoverflater. held substance in a manner known in the field of cosmetics. The product thus obtained is an excellent skin agent which is suitable for the treatment of damaged skin surfaces.

Eksempel 2Example 2

Fremgangsmåten ifølge eksempel 1 ble fulgt men plasma-proteinene og de uorganiske substanser ble behandlet ved 121°C i 35 minutter. The procedure of Example 1 was followed but the plasma proteins and inorganic substances were treated at 121°C for 35 minutes.

Eksempel 3Example 3

Fremgangsmåten ifølge eksempel 1 eller 2 ble fulgt men griseblod ble anvendt, og produktet erholdt etter varme-behandling ble anvendt for tilførsel av mangel på sporelementer til griser per se ved påføring som salve på huden eller ved peroral administrering. The procedure according to example 1 or 2 was followed, but pig blood was used, and the product obtained after heat treatment was used for supplying trace element deficiencies to pigs per se by application as an ointment to the skin or by oral administration.

Eksempel 4Example 4

Fremgangsmåten ifølge eksempel 1 ble fulgt men humant blod tilhørende gruppe B ble anvendt. The procedure according to example 1 was followed but human blood belonging to group B was used.

Eksempel 5Example 5

Fremgangsmåten ifølge eksempel 1 ble fulgt men 70 ml Héviz medisinsk vann ble anvendt i stedet for den vandige løsning inneholdende uorganiske substanser. The procedure according to Example 1 was followed but 70 ml of Héviz medicinal water was used instead of the aqueous solution containing inorganic substances.

Eksempel 6Example 6

Fremgangsmåten ifølge eksempel 1 til 4 ble fulgt men proteinet ble omsatt med medisinsk vann fra Csåszårbath, Budapest. The procedure according to examples 1 to 4 was followed but the protein was reacted with medicinal water from Csåszårbath, Budapest.

Eksempel 7Example 7

Fremgangsmåten ifølge eksempel 1 til 4 ble fulgt men et mineralsk vann, f.eks. Parådivann ble anvendt i stedet for den vandige løsning fremstilt i eksempel 1. The procedure according to examples 1 to 4 was followed but a mineral water, e.g. Purified water was used instead of the aqueous solution prepared in example 1.

Eksempel 8Example 8

Til 10 liter blodplasma fra okse ble tilsatt 25 ml vann, 100 mg kobbersulfat og 100 mg sinksulfat, og reaksjonsblandingen ble holdt ved 121°C i 60 minutter. Det erholdte produkt ble påført ved sprøyting på huden eller håret på dyr eller ved vanning for behandling av sykdommer på grunn av mangel av sporelementer. To 10 liters of blood plasma from an ox, 25 ml of water, 100 mg of copper sulfate and 100 mg of zinc sulfate were added, and the reaction mixture was kept at 121°C for 60 minutes. The product obtained was applied by spraying to the skin or hair of animals or by irrigation for the treatment of diseases due to a lack of trace elements.

EksempelExample

Til det tørre plasmapulver erholdt fra humant blod fra gruppe 0 ifølge eksempel 1 ble tilsatt 400 ml vann og 0,5 ml kommersielt "Béres-csepp" inneholdende sporelementer. Reaksjonsblandingen ble behandlet ved 121°C i 35 minutter og ble deretter bearbeidet til en krem på kjent måte. Kremen er egnet for regenerering av hud med varmeskader. To the dry plasma powder obtained from human blood from group 0 according to example 1, 400 ml of water and 0.5 ml of commercial "Béres-csepp" containing trace elements were added. The reaction mixture was treated at 121°C for 35 minutes and was then processed to a cream in a known manner. The cream is suitable for the regeneration of skin with heat damage.

Eksempel 10Example 10

Fremgangsmåten ifølge eksempel 1 til 9 ble fulgt men proteinet inneholdende substanser ble varmebehandlet i et medium fritt for oxygen eller nærvær av en inert gass. The procedure according to examples 1 to 9 was followed but the protein containing substances was heat treated in a medium free of oxygen or the presence of an inert gas.

Eksempel 11Example 11

Fremgangsmåten ifølge eksempel 1 eller 9 ble fulgt, men preparatet ble fremstilt fra vevet fra organismen av den angjeldende person. The procedure according to example 1 or 9 was followed, but the preparation was prepared from the tissue of the organism of the person concerned.

Eksempel 12Example 12

100 ml humant blod ble separert for plasmavæske og blodelementer. Til plasmaet ble tilsatt 80 ug jern(III)sulfat, 8 ug mangan(II)klorid, 40 ug sinkklorid, 40 ug kobbersulfat, 80 jag kaliumklorid, 4 ug hver av borsyre, sølvnitrat og gull (III)klorid, og reaksjonsblandingen ble omrørt ved 36°C i 30 minutter. Den erholdte løsning ble påført parenteralt. 100 ml of human blood was separated for plasma fluid and blood elements. To the plasma was added 80 µg iron (III) sulfate, 8 µg manganese (II) chloride, 40 µg zinc chloride, 40 µg copper sulfate, 80 µg potassium chloride, 4 µg each of boric acid, silver nitrate and gold (III) chloride, and the reaction mixture was stirred at 36°C for 30 minutes. The obtained solution was applied parenterally.

Eksempel 13Example 13

Til 8 g tørt, hydrofilt humant blodplasma ble tilsatt 400 ml fysiologisk natriumklorid hvori 160 ug jern.(II)sulfat, 16 ug mangan(II)klorid, 80 ug sinkklorid, 80 pg kobbersulfat, To 8 g of dry, hydrophilic human blood plasma was added 400 ml of physiological sodium chloride in which 160 ug of iron (II) sulfate, 16 ug of manganese (II) chloride, 80 ug of zinc chloride, 80 pg of copper sulfate,

60 ug kaliumklorid og 8 |ug hver av sølvnitrat, borsyre og gull(III)klorid på forhånd var blitt oppløst. Reaksjonsblandingen ble sterilisert i. en forseglet beholder ved 121°C 60 µg of potassium chloride and 8 µg each of silver nitrate, boric acid and gold(III) chloride had previously been dissolved. The reaction mixture was sterilized in a sealed container at 121°C

i 30 minutter. Den erholdte løsning ble påført parenteralt. for 30 minutes. The obtained solution was applied parenterally.

Claims (7)

1. Fremgangsmåte for fremstilling av medisinske kosmetiske preparater, karakterisert ved at det for fremstillingen av preparatet anvendes humane blodkarakteristika for art, type av den givende levende organisme, f.eks. tilhørende blodtype A, B, AB, 0, Rh-positiv, Rh-negativ eller elementene derav og/eller proteiner erholdt derfra per se og/eller ved omsetning av disse med sporelementer, eventuelt sammen med kjente substanser som generelt anvendes for fremstilling av kosmetiske preparater.1. Procedure for the production of medical cosmetic preparations, characterized in that human blood characteristics are used for the preparation of the preparation for species, type of the donor living organism, e.g. associated blood type A, B, AB, 0, Rh-positive, Rh-negative or the elements thereof and/or proteins obtained from them per se and/or by reacting these with trace elements, possibly together with known substances that are generally used for the production of cosmetic preparations. 2. Fremgangsmåte ifølge krav 1, karakterisert ved at det anvendes i preparater administrert til dyr blodet og/eller elementene derav avledet fra de gitte arter av dyrene.2. Method according to claim 1, characterized in that the blood and/or its elements derived from the given species of animals are used in preparations administered to animals. 3. Fremgangsmåte ifølge krav 1 eller 2, karakterisert ved at proteinet inneholdende substansen omsettes med naturlig vann og/eller mineralsk vann, medisinsk vann og de originale substanser inneholdt deri. •3. Method according to claim 1 or 2, characterized in that the protein containing the substance is reacted with natural water and/or mineral water, medical water and the original substances contained therein. • 4. Fremgangsmåte ifølge krav 1, 2 og 3, karakterisert ved at proteinet inneholdende substanser omsettes i et medium fritt for oxygen og/eller en inert gassatmosfære.4. Method according to claims 1, 2 and 3, characterized in that the protein-containing substances are reacted in a medium free of oxygen and/or an inert gas atmosphere. 5. Fremgangsmåte ifølge krav 1, 3 og 4, karakterisert ved at preparatet fremstilles for en gitt person ved anvendelse av blodet eller vevet fra den gitte person.5. Method according to claims 1, 3 and 4, characterized in that the preparation is prepared for a given person by using the blood or tissue from the given person. 6. Fremgangsmåte for omsetning av "humant blodplasma med sporelementer, -uorganiske substanser og for anvendelse av det erholdte produkt, karakterisert ved at blodplasma omsettes med uroganiske salter med en temperatur på 70°C og at den erholdte løsning påføres parenteralt.6. Procedure for turnover of "human blood plasma with trace elements, inorganic substances and for use of the obtained product, characterized in that blood plasma is reacted with inorganic salts at a temperature of 70°C and that the resulting solution is applied parenterally. 7. Fremgangsmåte for omsetning av proteinet erholdt fra humant blodplasma med uorganiske substanser og anvendelse av det erholdte produkt, karakterisert ved at proteinet erholdt fra blodplasmaet omsettes med uorganiske substanser i vandig medium ved en temperatur på 90 til 140°C, hvoretter den erholdte løsning steriliseres og påføres for regenerering av indre sår på organismen, f.eks. intravenøst.7. Procedure for reacting the protein obtained from human blood plasma with inorganic substances and use of the obtained product, characterized in that the protein obtained from the blood plasma is reacted with inorganic substances in an aqueous medium at a temperature of 90 to 140°C, after which the obtained solution is sterilized and applied for the regeneration of internal wounds on the organism, e.g. intravenously.
NO852427A 1983-10-17 1985-06-14 PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS NO852427L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU833582A HUT37342A (en) 1983-10-17 1983-10-17 Process for production of preparatives for medical cosmetics

Publications (1)

Publication Number Publication Date
NO852427L true NO852427L (en) 1985-06-14

Family

ID=10964641

Family Applications (1)

Application Number Title Priority Date Filing Date
NO852427A NO852427L (en) 1983-10-17 1985-06-14 PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS

Country Status (12)

Country Link
JP (1) JPS61500358A (en)
KR (1) KR850700008A (en)
AU (1) AU3551084A (en)
DE (1) DE3490488T1 (en)
DK (1) DK273585A (en)
FI (1) FI852341A0 (en)
GB (1) GB2164848A (en)
HU (1) HUT37342A (en)
NL (1) NL8420264A (en)
NO (1) NO852427L (en)
SE (1) SE8502997D0 (en)
WO (1) WO1985001653A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1243957A (en) * 1983-06-03 1988-11-01 Laszlo Bogdany Compositions for cosmetic, health- and body- preserving use
FR2572287A1 (en) * 1984-10-26 1986-05-02 Caola Kozmetikai Process for preparing medicinal cosmetic compositions
AU617661B2 (en) * 1987-02-24 1991-12-05 Thermalife International Pharmaceuticals Limited A method for manufacturing cosmetical, health and body care products
US5527779A (en) * 1988-03-23 1996-06-18 Top Gold Pty Limited Topically applied gold organic complex
NZ228367A (en) * 1988-03-23 1992-02-25 Smithkline Beecham Corp Topical composition containing a gold compound for treating inflammatory conditions
US5013726A (en) * 1989-09-12 1991-05-07 Ivy Jeffery W External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion
US5124320A (en) * 1989-09-12 1992-06-23 Ivy Jeffery W An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion
US20070048387A1 (en) * 2005-09-01 2007-03-01 Edwards Jeffrey D Tissue disruption treatment and composition for use thereof
CN103033632B (en) * 2012-12-12 2014-10-22 英科新创(厦门)科技有限公司 Reverse typing colloidal gold kit for ABO blood groups and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU101771A1 (en) * 1954-05-04 1900-01-01 А.А. Дыскин The carbonation method of citrate donated blood and a device for implementing the method
SU523695A1 (en) * 1973-12-14 1976-08-05 Курганский Научно-Исследовательский Институт Экспериментальной И Клинической Ортопедии И Травматологии Method to stop bleeding
SU777903A1 (en) * 1978-12-26 1981-12-15 Ленинградский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Гематологии И Переливания Крови Method of producing aminoacid compound for parenteral nutrition
SU741877A1 (en) * 1979-06-06 1980-06-25 За витель Р. Н. Ходанова Allergic desease treating method

Also Published As

Publication number Publication date
DK273585D0 (en) 1985-06-17
SE8502997L (en) 1985-06-17
GB8514467D0 (en) 1985-07-10
DE3490488T1 (en) 1985-10-17
WO1985001653A1 (en) 1985-04-25
JPS61500358A (en) 1986-03-06
FI852341L (en) 1985-06-12
GB2164848A (en) 1986-04-03
KR850700008A (en) 1985-10-21
FI852341A0 (en) 1985-06-12
DK273585A (en) 1985-06-17
NL8420264A (en) 1985-09-02
AU3551084A (en) 1985-05-07
HUT37342A (en) 1985-12-28
SE8502997D0 (en) 1985-06-17

Similar Documents

Publication Publication Date Title
CA1277599C (en) Vanadium - peroxide compositions as insulin mimickers
CA2298645C (en) Use of physiologically acceptable vanadium compounds, salts and complexes
NO852427L (en) PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS
Sander et al. Evidence for function of a metal ion in the activity of dihydroorotase from Zymobacterium oroticum
KR100828494B1 (en) A composition of a cosmetic essense and the method of prepating it for improvenent of wrinkle
US4863897A (en) Protein and mineral water-containing cosmetic compositions
US4839347A (en) Composition for treating dehydration
JP2004510402A (en) Acidic solution of poorly soluble group IIA complex
FR2546754A1 (en) COSMETIC AGENTS FOR THE CARE OF HEALTH AND BODY
Carruthers et al. Biochemistry and physiology of epidermis
RU2399367C1 (en) Method of thrombin clotting time optimisation for newborn piglets with anaemia
Hirsch Tissue Autoxidation Inhibitors: I. The Inhibition of DOPA Autoxidation by Extracts from Normal and Neoplastic Tissues
FR2572287A1 (en) Process for preparing medicinal cosmetic compositions
Nomura et al. CIII The Capillary in the Human Vestibular Labyrinth: A Histochemical Staining Technique
US3017325A (en) Therapeutic composition for topical application and method of applying the same
Sheker et al. Silver allantoinate for the topical treatment of burns
BE900935A (en) Prodn. of medicinal cosmetic compsns. - from human blood
Carroll Phenolsulfotransferase in the developing rat
RU2392927C1 (en) Method of normalising antiplasmin level in anemia of newborn calves and pigs
RU2406483C2 (en) METHOD OF α2 ANTIPLASMIN LEVEL REDUCTION IN NEWBORN PIGLETS WITH ANAEMIA
RU2818836C1 (en) Method for iron deficiency anemia correction in sucking calves
RU2383334C1 (en) Method for normalisation of fibrin content in blood in neonatal piglets with anaemia
CN103232538B (en) Sulfhydrylation modified collagen calcium compound
SU829115A1 (en) Method of treating and prophylaxis of gastro-intestinal disturbances of agricultural animals
RU2349308C1 (en) METHOD OF α2 ANTIPLASMIN LEVEL STABILISATION FOR NEWBORN PIGLETS WITH ANAEMIA